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Preeclampsia (PE) is the most serious complication of pregnancy that causes maternal and fetal 
morbidity and mortality. Although the exact pathophysiology of PE is unknown, a large number of 
studies have shown that abnormalities in nitric oxide (NO) synthesis may contribute to the development 
of this disorder. There are some evidences that polymorphisms of the endothelial nitric oxide synthase 
(eNOS) gene affect NO production and have been associated with hypertension and PE in some 
populations. Therefore the aim of this study was to assess the relation of the Glu298Asp eNOS 
polymorphism and PE in an Iranian population. We compared the frequency of the Glu298Asp 
polymorphism in 147 women with PE and 137 healthy pregnant control subjects by polymerase chain 
reaction- restriction fragment length polymorphism (PCR-RFLP) method. The frequencies of Glu298Asp 
genotypes were significantly different between PE women and controls (p < 0.001). The frequency of 
Asp allele was 0.32 in PE patients and 0.20 in controls and was significantly different (p < 0.001). The 
risk of PE was 2.4 fold in pregnant women with Asp allele. In conclusion, the Asp allele could be a risk 
factor for PE in South East of Iran. 
 





Preeclampsia (PE) is one of the most severe problems of 
pregnancy and has a familial predisposition. Although the 
exact pathophysiology of preeclampsia is not clear, 
several maternal genetic variations, in conjunction with 
environmental factors, may predispose to the develop-
ment of the disease (Salonen et al., 2000). Genetic 
factors and mutilation of nitric oxide (NO)–mediated 
vasodilation appear to have important roles in progress of 
PE (Salonen et al., 2000; Broughton et al., 2001). The 
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a candidate gene for the development of PE has been 
investigated by many studies (Arngrimsson et al., 1997; 
Lade et al., 1999; Yoshimura et al., 2000; Tempfer et al., 
2001). Furthermore, some evidences demonstrated 
familial pregnancy-induced hypertension associated with 
a locus in the region of chromosome 7q36, which also 
encodes the eNOS gene (Lade et al., 1999; Lewis et al., 
1999). The eNOS is expressed in the endothelium, 
encoded by a 26 exon gene with a total size of 21 kb and 
encodes a mRNA of 4052 nucleotides (Marsden et al., 
1993). The eNOS gene has a common polymorphism at 
position 298 (Glu298Asp) which has been associated 
with both altered NO production (Wang et al., 1997) and 
with vascular disorders including hypertension (Benjafield 
and Morris, 1999),   myocardial   infarction   (Hibi   et   al.,  


































Figure 1. The Glu298Asp polymorphism of eNOS gene was shown by electrophoresis on 2% 
agarose gel. Lane 3: 50-bp DNA ladder; lane 2 and 7: Glu/Glu genotype; lane 5 and 6: 




1998), coronary artery spasm (Yoshimura et al., 2000), 
stroke (Elbaz et al., 2000), and renal disease (Noiri et al., 
2002). Yoshimura et al. (2000) reported the association 
of the Asp allele with severe PE in Japanese but they did 
not observe any association between this polymorphism 
and PE in Bangladesh (Yoshimura et al., 2003). There 
are conflicting results about the correlation between 
Glu298 Asp polymorphism and PE in different ethnic 
groups. In Eastern Finland  and USA, it was revealed  
that there was no evidence for the  association between 
this polymorphism and PE (Hakli et al., 2003; Landau  et 
al., 2004) while Tempfer et al. (2004) showed  a 
significant differences between them in USA.  
Since there is not any report in Iranian population, the 
aim of this study was to investigate the association 
between Glu298 Asp polymorphism of the eNOS gene 
and PE in South East of Iran.  
 
 




With Institutional Review Board approval and written informed 
consent from all subjects, we obtained blood samples for 
genotyping from women delivering at Ali-ebn-abitaleb hospital in 
Zahedan. Women were considered to have PE if they met the 
1996/2000 American College of Obstetricians and Gynecologists 
criteria for the definition of PE: Systolic blood pressure > 140 mm 
Hg or diastolic blood pressure > 90 mm Hg, occurring on at least 
two occasions 6 h apart, with proteinuria > 0.3 g/L in a 24 h 
specimen, or a proteinuria dipstick reading of 2+ on a random urine 
collection, with no pre-pregnancy history  of  essential  hypertension  
or hypertension before 20 weeks gestation. Blood pressures were 
determined using the automated blood pressure module of a 
Hewlett-Packard M1176A model 66 (Hewlett-Packard, Andover, 
MA) with the patient in the supine position. A total of 147 women 
with PE were genotyped and compared with 137 healthy 





Blood samples were obtained and genomic DNA was isolated from 
peripheral blood by DNA extraction Kit (Roche, Germany). The 
eNOS polymorphism of interest, Glu298Asp, was detected using a 
polymerase chain reaction (PCR)–based restriction enzyme 
analysis in Zahedan Cellular and Molecular Research Center. 
In brief, this exonic fragment was amplified by PCR with a 
forward primer 5´- GAC CCT GGA GAT GAA GGC AGG AGA-3´ 
and reverse primer 5´- ACC TCC AGG ATG TTG TAG CGG TGA-
3´ (Hibi et al., 1998). The reaction performed according to the 
protocol as previously described, except for the annealing step 
which was at 60ºC (Salimi et al., 2010). The 517 bp PCR product 
was digested overnight at 37°C with 10 units of the BanII restriction 
enzyme (Fermentas, Lithuania). The digestedPCR products were 
run on 2% agarose gel and visualized by ethidium bromide staining. 
The G wild type allele was not digested and produced a 517 bp 
fragment, whereas the variant T allele was digested into 346 and 





All statistical analyses were performed with SPSS V-11.5. The 
differences between groups were examined by χ2 tests or an 
independent student t-test for quantitative parameters. Allele 
frequencies were calculated by the gene counting method. The 
frequencies of the alleles and  genotypes  were  analyzed  between 




Table 1. Demographic characteristics of preeclamptic patients and controls.  
 
Demographic characteristic Preeclampsia, N = 147 Controls, N = 137 p Value 
Age (year) 28.1±7.7 26.3±6.1 NS 
Gestational age (weeks) 36.6 ± 3.6 38.2 ± 2.8 0.002 
Birth weight (g) 2789 ± 829 2993 ± 666 NS 
Diastolic blood pressure (mm Hg)  96 ± 8.7 69.7 ± 9.1 0.0001 
Systolic  blood pressure (mm Hg) 152.2 ± 14.5 111.9 ± 11.9 0.0001 
Primiparity (%) 0.42 0.29 0.015 
Family history of preeclampsia (%) 0.31 0.37 NS 
 
Race 
Persian (%) 25 39 
0.011 Baloch  (%) 44 43 
Afghan  (%) 31 18 
 




Table 2. Genotype and allele frequencies of Glu298Asp polymorphism of the eNOS gene in preeclamptic patients and controls. 
 
4b/a polymorphism Pre-eclampsia, N = 147 Controls, N = 137 χ² P Value OR (95%) 
Glu/Glu, n (%) 61 (41.5) 86(63) 
13.3 0.001 
 
Glu/Asp, n (%) 78(53) 48(35)  
Asp/Asp, n (%) 8(5.5) 3(2)  
 
Glu/Asp + Asp/Asp (%) 86(58.5) 51(37) 12.8 0.0001 2.4(1.5 - 3.8) 
Glu (%) 68 80 11.1 0.001  




patients and control groups by the χ2 test. The odds ratio (OR) and 
95% confidence intervals (CI) were also estimated. The χ2 test was 
used for deviation of genotype distribution from Hardy-Weinberg 
equilibrium. Logistic regression analysis was employed to 
determine the relations of gene polymorphisms and other risk 






The clinical and biochemical parameters of the controls 
and PE women are shown in Table 1. 
Maternal age and family history of PE did not differ 
significantly between two groups. As expected, systolic 
and diastolic blood pressure and primiparity were signifi-
cantly higher and gestational age was significantly lower 
in PE women. Although birth weight was lower in PE 
women, the difference was not significant. 
The frequencies of ethnic groups (Persian, Balooch 
and Afghan) were significantly different between PE 
women and controls (P = 0.03) and the risk of PE was 
two fold in Afghan women in contrast to other groups 
(OR, 2 [95% CI, 1.1 to 3.8]; P = 0.01). 
Allele frequencies of Glu298Asp polymorphism were in 
Hardy Weinberg equilibrium. The distribution of  genotype 
and allele frequencies of Glu298Asp polymorphism of 
eNOS gene was compared between PE patients and 
controls (Table 2). 
The frequencies of Glu/Glu, Glu/Asp and Asp/Asp 
genotypes were 46, 47 and 10% in PE patients and 63, 
35 and 2 in healthy pregnant women, respectively and 
were significantly different (p < 0.001). The frequency of 
Asp allele was 0.32 in PE patients and 0.20 in controls 
and was significantly different (p < 0.001). The risk of PE 
was 2.4 fold in pregnant women with Asp allele (Glu/Asp 
+ Asp/Asp) in contrast to control women without Asp 
allele (OR, 2.4 [95% CI, 1.5 to 3.8]; P = 0.0001). 
There was no correlation between Glu298Asp polymer-
phism of eNOS gene and the onset and severity of PE. 
Moreover, there was no variation in Glu298Asp 
polymorphism in different races. Multiple regression 
analysis revealed that Afghan race, gravity and presence 






PE is the most serious complication of pregnancy 
influencing    both    fetal   and   maternal   morbidity   and  




Table 3. Multiple logistic regression analysis with forward stepwise selection (Wald). 
  
Risk factor B S. E. Wald df Sig. Exp (B) 
95%  CI 
Lower Upper 
Afghan  race 0.8 0.3 7.1 1 0.008 1.5 2.5 4 
Primigravida   0.72 0. 27 7.4 1 0.007 2.1 1.2 3.5 
Glu/Asp + Asp/Asp genotype 0.95 0.25 13.9 1 0.0001 2.6 1.6 4.2 




mortality. The exact pathophysiology of PE remains 
unknown, however genetic and environmental factors are 
reported to be important (Broughton, 2001). There is 
several maternal genetic variations in conjunction with 
environmental factors that may predispose to the deve-
lopment of the disease (Salonen et al., 2000; Broughton, 
2001). In the first half of the pregnancy, systemic 
arteriolar vasodilation increase blood volume and cardiac 
output and decrease blood pressure. These changes are 
probably dependent on endothelial NO production and 
deficiency in NO production could be a risk factor for PE 
(Buhimschi et al., 1998; Landau et al., 2004). NO is 
synthesized by eNOS from L-Arginine and molecular 
oxygen in the endothelium. Therefore eNOS gene that 
encodes endothelial NO synthase is a candidate gene for 
PE (Lade et al., 1998; Buhimschi et al.; 1998; Kobashi et 
al., 2001). Arngrfmsson et al. (1997) reported the 
localization of a familial pregnancy-induced hypertension-
susceptibility locus in the region of chromosome 7q36 
encoding the eNOS gene.  
In this study, we assessed the relation between the 
common G894T polymorphism of eNOS gene, which 
encodes an amino acid substitution (Glu298Asp) 
between preeclamptic patients and controls. The 
mechanisms by which eNOS Asp298 polymorphism 
might reduce NO bioavailability have been studied. The 
most probable mechanism have shown that eNOS 
Asp298 is exposed to selective proteolytic cleavage in 
endothelial cells and vascular tissues, and this could 
explain reduced vascular NO generation in homozygote 
subjects for this variant (Tesauro et al., 2000). Further-
more, some evidences suggest that preeclampsia is 
associated with decreased levels of NO and increased 
levels of circulating inflammatory cytokines due to single 
nucleotide polymorphisms (Sharma et al., 2011). 
In the present study, we found that the Glu298Asp 
polymorphism of eNOS gene genotype (p < 0.001) and 
allele (p < 0.001) frequencies were significantly different 
between the two groups and Asp allele being more 
frequent in PE women. In women with Asp allele 
(Glu/AspI + Asp/Asp), the risk of PE was 2.4 fold (OR, 2.4 
[95% CI, 1.5 to 3.8]; P = 0.0001).  
There are several studies about the association of 
Glu298Asp polymorphism of eNOS gene and PE in 
different countries.  However, most of the studies failed to 
document an association between rare allele (298Asp) 
frequency and PE;  in  other   studies,   the   investigators 
found an association between Glu298Asp polymorphism 
and PE. 
Yoshimura et al. (2000) reported this polymorphism as 
a risk factor for developing severe PE in Japanese 
population. Their study revealed that the frequency of the 
Glu298Asp variant was 28.8% in severe PE group and 
14.1% in control group. Moreover, in another study, they 
demonstrated an association between placental 
abruption and Asp298 allele in Japanese women 
(Yoshimura et al., 2001). Later, they replicated their 
investigation in a developing country (Bangladesh) and 
they did not find any association between PE and rare 
allele frequency (Yoshimura et al., 2003). In Eastern 
Finland, it was demonstrated that there was no evidence 
for the association between this polymorphism and PE 
(Hakli et al., 2003). 
Moreover in other studies in USA (Landau et al., 2004), 
Korea (Kim et al., 2006), United Kingdom (Yu et al., 
2006), India (Singh et al., 2009) and Germany (Hocher et 
al., 2008) did not find any relation between PE and this 
polymorphism. 
In a meta analysis study, Medica et al. (2007) carried 
out a systematic research on published case-control 
studies on Glu298Asp polymorphism of eNOS gene (9 
analyses involving 1055 patients and 1788 controls) and 
reported that single polymorphism did not have a major 
effect on PE. 
Chen et al. (2007) in Taiwan concluded that the 
polymorphisms in the eNOS gene may be protective 
against PE in a Chinese population, in contrast to the 
results in the Japanese population. 
In another study, a significant difference in the allele 
frequency and genotype distribution of this polymorphism 
and PE have been shown in USA (Tempfer et al., 2001). 
Furthermore, other investigators evaluated the relation of  
three common polymorphisms of eNOS  gene (4a/b, 
Glu298Asp and T-786C) and assessed  synergic effect of 
these SNPs. Serrano et al. (2004) in Colombia concluded 
that the eNOS Glu298Asp polymorphism and the 
Asp298-786C-4b haplotype are risk factors for PE; in 
consistent with our results, they found in women 
homozygous for the Asp298 allele, the adjusted OR for 
PE was 4.60 (95% confidence interval [CI], 1.73 to 12.22) 
compared with carriers of the Glu298 allele. Sandrim et 
al. (2008) in Brazil showed that the haplotype 'C Glu a' 
was more common in women with gestational hyperten-
sion and PE than in healthy  controls.   Recent   study   in  




India showed that there was no relation between 
individual eNOS gene polymorphisms and hypertensive 
disorders of pregnancy in North Indian women. But the 
presence of rare alleles at all the three sites in eNOS 
seemed to increase the risk of PE (Aggrawal et al., 
2010). What we have seen in South East of Iran was in 
agreement with studies in Colombia, USA and Japan and 
was in contrast to with studies in Finland, Korea, United 
Kingdom and India. 
This discrepancy is common in association studies and 
is due to the unlike genetic and environmental back-
grounds, inclusion and exclusion criteria for PE women 
and controls and sample size volume; however, with 
attention to meta analysis study, it is more probable that 
the small study volume is the most important reason of 
this discrepancy. 
In conclusion, this study demonstrated that maternal 
eNOS Glu298Asp polymorphism is associated with PE 
and the frequency of Asp allele was significantly higher in 
PE patients than healthy controls. The risk of PE was 2.4 
fold in pregnant women with Asp allele contrast to control 
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